A single injection cut lipoprotein(a) by 97% at forty-eight weeks

Design

First-in-human, randomised, double-blind, placebo-controlled phase 1 trial, seven single-dose cohorts

Population

70 otherwise healthy adults aged 18-55 with raised lipoprotein(a) at a single site in China

Primary outcome

Investigator-assessed adverse events within 24 weeks

Effect

No serious or drug-related adverse events; median lipoprotein(a) at 48 weeks fell 53% (9 mg) to 97% (600 mg); 96% (-208 nmol/L) in the cohort with baseline above 200 nmol/L given 225 mg

Lipoprotein(a) is largely genetically set, unmoved by statins, and still has no licensed treatment aimed at it. Kylo-11 is a small interfering RNA designed for very long duration of action. This first-in-human phase 1 trial gave 70 otherwise healthy adults aged 18-55 with raised lipoprotein(a) a single subcutaneous dose or placebo across seven dose cohorts at one site in China, and followed them for a median of 337 days.

Safety was the primary endpoint and was unremarkable: 53% had an adverse event by 24 weeks, mostly grade 1-2, with no injection-site reactions, no serious adverse events, none judged drug-related, and no deaths. The pharmacodynamic result is what draws attention. At 48 weeks after one dose, median lipoprotein(a) was down 53% in the 9 mg cohort and 97% in the 600 mg cohort; in the cohort selected for baseline concentrations above 200 nmol/L, 225 mg gave a 96% reduction, an absolute fall of 208 nmol/L.

Nothing here tells you whether lowering lipoprotein(a) prevents events — that is what the phase 3 outcome trials of this drug class are for, and they are not reported. What it does establish is that near-complete, year-long suppression from a single injection is achievable, which changes what a future dosing schedule could look like.

• No change to practice: lipoprotein(a)-lowering has no outcome evidence yet
• Continue measuring lipoprotein(a) once in patients with premature or familial atherosclerotic disease
• Manage conventional risk factors harder where lipoprotein(a) is raised — that remains the only available lever
• Note the population: healthy volunteers aged 18-55, not patients with vascular disease

Why it matters

It makes an annual injection a plausible dosing schedule for lipoprotein(a) lowering, if the outcome trials deliver.

Don't overread it

This is a phase 1 trial in healthy volunteers with a biomarker endpoint; it says nothing about cardiovascular events.

The statistics, in plain English

These reduction figures are medians with interquartile ranges rather than treatment effects against placebo, and they are secondary pharmacodynamic endpoints — the trial was powered for adverse events, not for them. A 97% fall in a biomarker is not evidence of clinical benefit: several drug classes have lowered a lipid marker convincingly and changed no outcome. The safety dataset is 57 exposed participants, far too small to detect uncommon harms.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.